
The FDA has given the green light to Novartis’ new heart failure drug, six weeks ahead of the scheduled date …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

